At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MURA Mural Oncology
Market Closed 12-27 16:00:00 EST
3.22
+0.04
+1.26%
盘后3.16
-0.06-1.86%
18:07 EST
High3.25
Low3.06
Vol189.18K
Open3.15
D1 Closing3.18
Amplitude5.97%
Mkt Cap55.00M
Tradable Cap40.95M
Total Shares17.08M
T/O593.64K
T/O Rate1.49%
Tradable Shares12.72M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in Its Artistry-1 Clinical Trial of Nemvaleukin, Its Lead Engineered Fusion Protein, in the Journal for Immunotherapy of Cancer
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology Q3 2024 GAAP EPS $(1.87) Beats $(1.98) Estimate, Cash, Cash Equivalents, And Marketable Securities Of $175.5M Are Expected To Fund Its Operations Into The Fourth Quarter Of 2025
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.